Discordant risk results were the least common: "C-low/G-high assigned to no CT" (n = 12), "C-low/G-high assigned to CT" (n = 18), "C-high/G-low assigned to no CT" (n = 25), and "C-high/G-low assigned to CT" (n = 25).
This may explain, in part, why we did not confirm the hypothesis that the "C-low/G-high assigned to no chemotherapy" risk group would have higher distress.
Rather, higher distress levels compared to the reference group were observed for the "C-low/G-high assigned to chemotherapy" and "C-high/G-low not assigned to chemotherapy".
Crossing clinical and genomic results, and accounting for trial assignment of discordant test results, yielded 8 groups: 1) "C-low/G-low", 2) "C-high/G-high", 3) "C-low/G-high assigned to no CT", 4) "C-low/G-high assigned to CT", 5) "C-high/G-low assigned to no CT", 6) "C-high/G-low assigned to CT", 7) "C-low/G-na", and 8) "C-high/G-na".
Associated with higher distress compared to the reference group were the groups: genomic profile not available (p = 0.002 and p < 0.001), "C-high/G-high" (p = 0.01) and the discordant groups "C-low/G-high assigned to CT" (p < 0.001) and "C-high/G-low assigned to no CT" (p < 0.001) (Table 6).
† Highest assigned grade if different between right and left side.
In this approach, the CR with high is assigned relatively high target detection probability.
The higher the assigned score, the higher the probability that the sequence is a true splice site.
Some of these have titles corresponding to known works by Leonardo, and the high values assigned to them suggest they were thought of as originals rather than copies.
For those in tech investing, this concern is perhaps most acute, given the generally high multiples assigned to the sector.
